» Authors » Rene-Marc Flipo

Rene-Marc Flipo

Explore the profile of Rene-Marc Flipo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 180
Citations 2239
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruyssen-Witrand A, Brusq C, Masson M, Bongard V, Salliot C, Poiroux L, et al.
Ann Rheum Dis . 2025 Jan; 84(1):49-59. PMID: 39874233
Objectives: To compare two strategies-a hydrocortisone replacement strategy and a prednisone tapering strategy-for their success in glucocorticoid discontinuation in patients with rheumatoid arthritis (RA) with low disease activity (LDA). Methods:...
2.
Triboulet F, Juge P, Truchetet M, Pham T, Roux N, Flipo R, et al.
RMD Open . 2025 Jan; 11(1. PMID: 39762124
Objective: To examine the course of interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in France on treatment with Janus kinase inhibitors (JAKis) using the MAJIK-SFR registry. Methods: Prospective national...
3.
Hamroun S, Couderc M, Flipo R, Sellam J, Richez C, Dernis E, et al.
RMD Open . 2024 Nov; 10(4). PMID: 39615886
Background: The impact of disease activity and treatment on fertility outcomes in patients with spondyloarthritis (SpA) has been little explored. This study aimed to describe median time to pregnancy (TTP)...
4.
Nguyen Y, Baron G, Hamamouche N, Belkhir R, Miconnet S, Soubrier M, et al.
Rheumatology (Oxford) . 2024 Nov; PMID: 39576675
Objectives: To evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among rheumatoid arthritis (RA) patients treated with anti-TNF therapies, and to...
5.
Ruyssen-Witrand A, Dimeglio C, Nogue E, Molinary N, Pham T, Gaujoux-Viala C, et al.
Clin Exp Rheumatol . 2024 Oct; 42(11):2141-2149. PMID: 39436731
Objectives: To compare the humoral response after a SARS-CoV-2 infection in an inflammatory rheumatic disease population with a healthy control population in a case-control study. Methods: Cases: between March and...
6.
Demouveaux A, Delclaux M, Goudot A, Duponchelle E, Cortet B, Flipo R, et al.
Joint Bone Spine . 2024 Apr; 91(4):105723. PMID: 38582363
No abstract available.
7.
Flipo R, Constantin A, Goupille P, Chartier M, Ohayon A, Mariette X
Clin Exp Rheumatol . 2024 Mar; 42(7):1377-1386. PMID: 38436358
Objectives: While multiple studies have investigated treatment persistence rates with intravenous abatacept, limited information is available about real-world treatment continuation with the subcutaneous form. The international ASCORE study described the...
8.
Larid G, Baudens G, Tiemdjo-Djimaffo G, Coquerelle P, Goeb V, Guyot M, et al.
Sci Rep . 2024 Jan; 14(1):1374. PMID: 38228719
The objectives of our study were to assess retention rate, safety, and predictive factors for retention of subcutaneous (SC) TNF inhibitors (TNFi) (adalimumab (ADA), etanercept (ETN), golimumab (GOL), and certolizumab...
9.
Juge P, Wemeau L, Ottaviani S, Desjeux G, Zhuo J, Vannier-Moreau V, et al.
RMD Open . 2023 Dec; 9(4). PMID: 38053461
Objectives: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). The objectives of this study were to estimate mortality rate in patients with RA-ILD and identify...
10.
Philippoteaux C, Delepine T, Cailliau E, Philippe P, Taisne N, Pascart T, et al.
Joint Bone Spine . 2023 Nov; 91(2):105670. PMID: 38036061
Objective: The EULAR task force recently published the difficult-to-treat RA (D2T RA) definition, however, a definition of D2T axSpA is still lacking and limitations in this definition exist. The objectives...